Neoadjuvant immunotherapy has shown promising short-term outcomes of perioperative treatments for resectable non-small cell lung cancer (NSCLC) and is expected to release long-term survival benefits.
Here, we reported the long-term prognostic value of 18F-FDG PET/CT over âˆ¼a 5-year follow-up.
